Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

Through its Impact Grants, the Cancer Research Institute funds projects that aim to advance defined scientific and technological goals. These awards stem from ongoing collaborations with individual donors and nonprofit organizations, and aim to address major challenges that would otherwise limit progress in cancer immunotherapy research and drug development. 

Technology Impact Award 

A program designed to challenge the world's leading scientists and out-of-the box thinkers to create a research plan and assemble a research team that will develop a new technology platform with the potential to transform the field of cancer immunotherapy.

Apply Here

Cancer Research Institute iAtlas

In partnership with Sage Bionetworks (Sage) and the Institute for Systems Biology (ISB), the Cancer Research Institute iAtlas is an online database and web resource designed to help basic and clinical researchers navigate immunological data across multiple tumor types.

Learn More

Focused Ultrasound and Cancer Immunotherapy Grant Program

The Cancer Research Institute (CRI) and the Focused Ultrasound Foundation (FUSF) established a partnership with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments. Grant projects address critical unanswered research questions that will help move the field towards new device/drug combination therapies.

Learn More

CRI-SU2C Cancer Immunology Translational Research Dream Team

In December 2012, CRI and Stand Up to Cancer (SU2C), announced their co-funding of the Cancer Immunology Translational Research Dream Team, whose research has focused on optimizing immunological checkpoint blockade combined with adoptive T cell transfer, two highly promising approaches to cancer immunotherapy.

Learn More

Fibrolamellar Cancer Foundation

In 2016, the Cancer Research Institute partnered with the Fibrolamellar Cancer Foundation (FCF), a nonprofit organization devoted to funding research in a rare but deadly form of liver cancer called fibrolamellar hepatocellular carcinoma (FHC), to provide $641,500 to four outstanding scientists whose research is focused on developing immunotherapies for patients with FHC.

Learn More

*Immunotherapy results may vary from patient to patient.

Top